NCT01929759 - Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

HIV Disease

Interventions

DRUG

Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)

Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks

Trial Locations (1)

Brigham and Women's Hospital, Boston